These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
138 related articles for article (PubMed ID: 35364250)
21. Efficacy of vortioxetine in patients with major depressive disorder reporting childhood or recent trauma. Christensen MC; Florea I; Loft H; McIntyre RS J Affect Disord; 2020 Feb; 263():258-266. PubMed ID: 31818787 [TBL] [Abstract][Full Text] [Related]
22. Vortioxetine in patients with major depressive disorder and high levels of anxiety symptoms: An updated analysis of efficacy and tolerability. Adair M; Christensen MC; Florea I; Loft H; Fagiolini A J Affect Disord; 2023 May; 328():345-354. PubMed ID: 36708956 [TBL] [Abstract][Full Text] [Related]
23. Current and Future Perspectives on the Major Depressive Disorder: Focus on the New Multimodal Antidepressant Vortioxetine. Orsolini L; Tomasetti C; Valchera A; Iasevoli F; Buonaguro EF; Fornaro M; Fiengo ALC; Martinotti G; Vellante F; Matarazzo I; Vecchiotti R; Perna G; Di Nicola M; Carano A; Di Bartolomeis A; De Giannantonio M; De Berardis D CNS Neurol Disord Drug Targets; 2017; 16(1):65-92. PubMed ID: 27781949 [TBL] [Abstract][Full Text] [Related]
24. A randomised, double-blind study in adults with major depressive disorder with an inadequate response to a single course of selective serotonin reuptake inhibitor or serotonin-noradrenaline reuptake inhibitor treatment switched to vortioxetine or agomelatine. Montgomery SA; Nielsen RZ; Poulsen LH; Häggström L Hum Psychopharmacol; 2014 Sep; 29(5):470-82. PubMed ID: 25087600 [TBL] [Abstract][Full Text] [Related]
25. Safety and tolerability of vortioxetine (15 and 20 mg) in patients with major depressive disorder: results of an open-label, flexible-dose, 52-week extension study. Jacobsen PL; Harper L; Chrones L; Chan S; Mahableshwarkar AR Int Clin Psychopharmacol; 2015 Sep; 30(5):255-64. PubMed ID: 26020712 [TBL] [Abstract][Full Text] [Related]
26. A meta-analysis of the efficacy of vortioxetine in patients with major depressive disorder (MDD) and high levels of anxiety symptoms. Baldwin DS; Florea I; Jacobsen PL; Zhong W; Nomikos GG J Affect Disord; 2016 Dec; 206():140-150. PubMed ID: 27474960 [TBL] [Abstract][Full Text] [Related]
27. Efficacy, safety, and tolerability of vortioxetine for the treatment of major depressive disorder in patients aged 55 years or older. Nomikos GG; Tomori D; Zhong W; Affinito J; Palo W CNS Spectr; 2017 Aug; 22(4):348-362. PubMed ID: 27869048 [TBL] [Abstract][Full Text] [Related]
28. What role for ▼vortioxetine? Drug Ther Bull; 2016 Mar; 54(3):30-3. PubMed ID: 26966120 [TBL] [Abstract][Full Text] [Related]
29. Safety, tolerability, and efficacy of vortioxetine (Lu AA21004) in major depressive disorder: results of an open-label, flexible-dose, 52-week extension study. Alam MY; Jacobsen PL; Chen Y; Serenko M; Mahableshwarkar AR Int Clin Psychopharmacol; 2014 Jan; 29(1):36-44. PubMed ID: 24169027 [TBL] [Abstract][Full Text] [Related]
30. The efficacy and safety of 5 mg/d Vortioxetine compared to placebo for major depressive disorder: A meta-analysis. Fu J; Chen Y Psychopharmacology (Berl); 2015 Jan; 232(1):7-16. PubMed ID: 24871704 [TBL] [Abstract][Full Text] [Related]
31. Vortioxetine (Brintellix) for depression. Med Lett Drugs Ther; 2013 Nov; 55(1430):93-5. PubMed ID: 24276501 [No Abstract] [Full Text] [Related]
32. A randomized, double-blind, placebo-controlled study of vortioxetine on cognitive function in depressed adults. McIntyre RS; Lophaven S; Olsen CK Int J Neuropsychopharmacol; 2014 Oct; 17(10):1557-67. PubMed ID: 24787143 [TBL] [Abstract][Full Text] [Related]
33. The impact of antidepressant treatments on family functioning in adults with major depressive disorder: a post hoc comparison of vortioxetine and agomelatine. François C; Nielsen R; Danchenko N; Williams V; Lançon C Curr Med Res Opin; 2017 Jun; 33(6):1057-1066. PubMed ID: 28277865 [TBL] [Abstract][Full Text] [Related]
34. Vortioxetine for the treatment of major depression. Dhir A Drugs Today (Barc); 2013 Dec; 49(12):781-90. PubMed ID: 24524096 [TBL] [Abstract][Full Text] [Related]
35. Efficacy of Vortioxetine on Cognitive Functioning in Working Patients With Major Depressive Disorder. McIntyre RS; Florea I; Tonnoir B; Loft H; Lam RW; Christensen MC J Clin Psychiatry; 2017 Jan; 78(1):115-121. PubMed ID: 27780334 [TBL] [Abstract][Full Text] [Related]
36. The safety and efficacy of vortioxetine for acute treatment of major depressive disorder: a systematic review and meta-analysis. Meeker AS; Herink MC; Haxby DG; Hartung DM Syst Rev; 2015 Mar; 4():21. PubMed ID: 25874839 [TBL] [Abstract][Full Text] [Related]
37. Vortioxetine for the treatment of depression. Pearce EF; Murphy JA Ann Pharmacother; 2014 Jun; 48(6):758-65. PubMed ID: 24676550 [TBL] [Abstract][Full Text] [Related]
38. [Vortioxetine: a new antidepressant to treat depressive episodes]. Colle R; Corruble E Encephale; 2016 Feb; 42(1):48-58. PubMed ID: 26358483 [TBL] [Abstract][Full Text] [Related]
39. Intravenous vortioxetine to accelerate onset of effect in major depressive disorder: a 2-week, randomized, double-blind, placebo-controlled study. Vieta E; Florea I; Schmidt SN; Areberg J; Ettrup A Int Clin Psychopharmacol; 2019 Jul; 34(4):153-160. PubMed ID: 31094901 [TBL] [Abstract][Full Text] [Related]
40. Vortioxetine versus Duloxetine in the Treatment of Patients with Major Depressive Disorder: A Meta-Analysis of Randomized Controlled Trials. Li G; Wang X; Ma D Clin Drug Investig; 2016 Jul; 36(7):509-17. PubMed ID: 27067232 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]